Literature DB >> 26824121

Author's Reply.

İsa Özyılmaz, Sinem Özyılmaz, Yakup Ergül, Alper Güzeltaş.   

Abstract

Entities:  

Year:  2015        PMID: 26824121      PMCID: PMC5336985     

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


× No keyword cloud information.
To the Editor, We would like to thank the authors of the letter for their interest and criticism on our study entitled “Heart rate variability improvement in children using transcatheter atrial septal defect closure “published in Anatol J Cardiol 2015 Mar 4 (1). Heart rate variability is a parameter used for the non-invasive evaluation of the neurohumoral control of the heart. One study reported reduced measurements of HRV in children with various congenital heart diseases (2). In another study, it has been shown that the dilatation of RV can decrease for up to 5 years after ASD closure (3). Some studies have published the normalization of RV size during the first 24 months after device closure (4). There may be other factors that affect the cardiac autonomic function besides atrial septal defect as the author mentions. However, Cansel et al. (4) found that the right ventricular diameter and pulmonary artery systolic pressure significantly decreased 6 months after transcatheter closure compared with values measured before transcatheter closure in patients with ASD. In our study, we concluded that HRV in children recovers approximately 6 months after transcatheter ASD closure. We did not report the dimensions of cardiac chambers before and after transcatheter closure. In our article, HRV after transcatheter ASD closure was compared with that of the control group. We did not declare that heart chambers reached normal values in 6 months. In our study, the 6th month HRV of patients who underwent transcatheter ASD closure approached the levels of the control group (1). HRV and reaching normal levels of right ventricular measurements are two different things. HRV could return to the normal range before the normalization of heart cavity due to hemodynamic improvement after transcatheter closure. Our study was designed using the heart rate variability data of Holter ECG in the previously published “’Holter Electrocardiographic Findings and P-wave Dispersion in Pediatric Patients with Transcatheter Closure of Atrial Septal Defects”’ study. A previously published part of this study was not used the heart rate variability data (5). Patient information [mean±SD, pulmonary artery pressure (mm Hg), Qp/Qs ratio, stretched diameter of ASD (mm), device defect ratio, device diameter (mm): 20.8±4.4, 2.1±0.4,16.8±3.8, 1.3±1.4, 19±4.2, respectively] were not written again because they were declared in this previously published study (1).
  5 in total

1.  Effects of transcatheter closure of atrial septal defects on heart rate variability.

Authors:  M Cansel; J Yagmur; N Ermis; N Acikgoz; H Taşolar; H Atas; K Muezzinoglu; H Pekdemir; R Ozdemir
Journal:  J Int Med Res       Date:  2011       Impact factor: 1.671

2.  Long-term follow-up study after closure of secundum atrial septal defect in children: an echocardiographic study.

Authors:  R A Meyer; J C Korfhagen; W Covitz; S Kaplan
Journal:  Am J Cardiol       Date:  1982-07       Impact factor: 2.778

3.  Clinical and haemodynamic correlates of heart rate variability in children with congenital heart disease.

Authors:  M Massin; G von Bernuth
Journal:  Eur J Pediatr       Date:  1998-12       Impact factor: 3.183

4.  Holter electrocardiography findings and P-wave dispersion in pediatric patients with transcatheter closure of atrial septal defects.

Authors:  Isa Ozyilmaz; Sinem Ozyilmaz; Hasan Tahsin Tola; Murat Saygi; Neslihan Kiplapinar; Cansaran Tanıdır; Yakup Ergul; Alper Guzeltas; Ender Odemis
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-10-08       Impact factor: 1.468

5.  Heart rate variability improvement in children using transcatheter atrial septal defect closure.

Authors:  İsa Özyılmaz; Yakup Ergül; Hasan Tahsin Tola; Murat Saygı; Erkut Öztürk; İbrahim Cansaran Tanıdır; Öyku Tosun; Sinem Özyılmaz; Mehmet Gül; Alper Güzeltaş; Ender Ödemiş; İhsan Bakır
Journal:  Anatol J Cardiol       Date:  2015-03-04       Impact factor: 1.596

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.